-- Board Appoints Aaron Berg as President & CEO --
-- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company.
"On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron as President & CEO," said Odysseas Kostas, MD, the Chairman of the Board. "No one knows the company better than Aaron, and we look forward to him contributing meaningfully as CEO."
"As I begin this new role, my focus is clear – to find ways to deliver value for investors, and to maximize the potential of VASCEPA®/VAZKEPA for patients," said Aaron Berg, President & CEO, Amarin. "I look forward to continuing to work with our Board of Directors and our tremendous team focusing on these priorities for the Company as we move forward."
Mr. Berg joined Amarin in November 2012 and has more than 30 years of biopharmaceutical industry experience. Mr. Berg initially served as Amarin's Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis, Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management. Prior to ...